What is the market impact of WEST PHARMACEUTICAL SERVICES INC's 10-Q filing?

West's 53% net income jump and aggressive $685.3M buyback signal management confidence, but the SmartDose divestiture and West Vantage decline raise questions about non-Proprietary growth drivers. Stock is essentially flat in extended hours at $416.67 (+0.14% vs. filing-time price). The strong earnings beat appears largely priced in given the +3.23% regular-session gain, and the $55.7M SmartDose gain is a one-time item that may temper enthusiasm.

What are the key takeaways from WEST PHARMACEUTICAL SERVICES INC's 10-Q filing?

Q3 net income jumped 52.9% YoY to $214.0M ($3.02 diluted EPS) from $140.0M ($1.92 diluted EPS). • Q3 net sales rose 8.7% YoY to $874.5M, driven by Proprietary Products segment growth of 12.6% to $728.8M. • Gross margin expanded to 39.7% from 36.6% a year ago; operating margin reached 30.6% vs. 20.8%. • Other expense (income) swung to $(51.2)M from $6.9M, including a $55.7M pre-tax gain on the SmartDose sale to AbbVie for $126.9M cash. • Share repurchases totaled $685.3M in the first nine months of FY2026, reducing basic shares outstanding to 70.4M from 72.2M.

$WST 10-Q — WEST PHARMACEUTICAL SERVICES INC

Summary

West Pharmaceutical Services filed its Q3 FY2026 10-Q, reporting net sales of $874.5M (+8.7% YoY) and diluted EPS of $3.02, up from $1.92 a year ago. Net income reached $214.0M, boosted by a $55.7M pre-tax gain from the July 1, 2026 sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie for $126.9M cash. Operating profit more than doubled to $267.4M from $167.6M, while the company deployed $685.3M in share repurchases over the first nine months of FY2026.

Key points

Q3 net income jumped 52.9% YoY to $214.0M ($3.02 diluted EPS) from $140.0M ($1.92 diluted EPS).
Q3 net sales rose 8.7% YoY to $874.5M, driven by Proprietary Products segment growth of 12.6% to $728.8M.
Gross margin expanded to 39.7% from 36.6% a year ago; operating margin reached 30.6% vs. 20.8%.
Other expense (income) swung to $(51.2)M from $6.9M, including a $55.7M pre-tax gain on the SmartDose sale to AbbVie for $126.9M cash.
Share repurchases totaled $685.3M in the first nine months of FY2026, reducing basic shares outstanding to 70.4M from 72.2M.

Financial results

PeriodQ3 FY2026

ResultBeat

Revenue$874.5M

Revenue YoY+8.7%

EPS$3.02

Net income$214M

Gross margin39.7%

Op. margin30.6%

Market impact

Stock is essentially flat in extended hours at $416.67 (+0.14% vs. filing-time price). The strong earnings beat appears largely priced in given the +3.23% regular-session gain, and the $55.7M SmartDose gain is a one-time item that may temper enthusiasm.

Why this matters

West's 53% net income jump and aggressive $685.3M buyback signal management confidence, but the SmartDose divestiture and West Vantage decline raise questions about non-Proprietary growth drivers.

Sector context

West's biologics exposure grew to 43% of net sales (from 41% a year ago), reinforcing its position as a key supplier to the GLP-1 and biologic drug delivery supply chain. The Proprietary Products segment's 12.6% growth outpaces broader pharma packaging peers.

Risk factors

The SmartDose sale removes a revenue stream; West Vantage segment sales declined 7.3% YoY to $145.7M in Q3. Foreign currency translation losses of $32.1M over nine months signal macro exposure. Cash and equivalents dropped $327.2M to $464.1M, largely due to aggressive buybacks.

Related tickers

$WST $ABBV

Related & recent SEC filings

All $WST SEC filings → $WST Congress trades → Research $WST →

$WST · WEST PHARMACEUTICAL SERVICES INC

Get filings like this before the market reacts.